7.7M
Downloads
289
Episodes
Dr Louise Newson is an award-winning physician, respected women’s hormone specialist, educator, and author committed to increasing awareness and knowledge of perimenopause, menopause, and lifelong hormone health. Each week, Louise dives into the newest research, treatments and hot topic issues, providing accessible, evidence-based information to empower your future health. Joined by fellow experts and special guests, with answers to your burning questions, Louise explores how hormones impact every aspect of our lives. Described as the “medic who kickstarted the menopause revolution”, Louise aims to empower a generation of women to have a greater understanding, choice and control over their treatment, bodies, minds and future health through their hormones. She is the creator of the award-winning free balance app, a Sunday Times bestselling author and the founder of the Newson Health clinic. With over three decades of clinical experience, Louise is a member of the Royal College of Physicians, a Fellow of the Royal College of GPs, a Visiting Fellow at Cambridge, a regular contributor to academic journals including the Lancet and the British Journal of General Practice, and has been awarded an honorary Doctorate of Health from Bradford University.
Episodes
Tuesday Feb 20, 2024
244 - Hot flush drug fezolinetant
Tuesday Feb 20, 2024
Tuesday Feb 20, 2024
On this week’s podcast, Dr Louise is joined by Dr Ashley Winter, a urologist and sexual medicine specialist, and Dr Sarah Glynne, a GP and menopause specialist who is a member of the research team at Newson Health and chairs a working party that promotes access to evidence-based menopause care for patients with breast cancer.
They discuss Fezolinetant – brand name Veoza – a new drug recently approved in the UK and other countries to treat moderate to severe hot flushes in menopausal women aged 45 to 60 years.
You can read an article about fezolinetant on the balance website here.
Related articles
Lederman S., Ottery F.D., Cano A., Santoro N., Shapiro M., Stute P., et al. (2023) 'Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study', Lancet, 401(10382):1091-102. doi.org/10.1016/S0140-6736(23)00085-5
Johnson K.A., Martin N., Nappi R.E., Neal-Perry G., Shapiro M., Stute P., et al. (2023), 'Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a Phase 3 RCT', J Clin Endocrinol Metab, 108(8):1981-97. Doi:10.1210/clinem/dgad058
Douxfils J., Beaudart C., Dogne J.M. (2023), 'Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant', Lancet, 402(10413):1623-5. doi.org/10.1016/S0140-6736(23)01634-3
Follow Dr Ashley Winter on X and Instagram @ashleygwinter
Follow Dr Sarah Glynne on Instagram @sarahglynne
Click here to find out more about Newson Health
Comments (1)
To leave or reply to comments, please download free Podbean or
As a GP with interest in the Menopause, this is fascinating. The safety data is really concerning.
Wednesday Feb 21, 2024
To leave or reply to comments,
please download free Podbean App.